Felix Lorenz
Seminars
Tuesday 15th September 2026
Boosting the Efficacy of TCR- & CAR-T Cells Using a Novel TGF-beta SWITCH Receptor
9:00 am
- SWITCH significantly increases potency of TCR- and CAR-T cells against tumors
- SWITCH receptor targeting TGF-beta, a key defense line of the hostile tumor microenvironment
- SWITCH may be suitable for efficacyenhancing autologous, allogeneic and in vivo T-cell therapies of solid and hematological tumors
